Trade in substandard and falsified medicines

Trade in substandard and falsified medicines

According to WHO, 10.5% of medicines in low- and middle-income countries are substandard or falsified (SF), which has a multidimensional impact on public health as well as severe economic and socioeconomic consequences. Constrained access, weak technical capacity and poor governance contribute to th...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Hagen, N, Hauk, C, Heide, L
Andere auteurs:	Brombacher, D
Formaat:	Book section
Taal:	English
Gepubliceerd in:	Nomos 2022

Gelijkaardige items

Identification of substandard and falsified medicines: influence of different tolerance limits and use of authenticity inquiries
door: Hauk, C, et al.
Gepubliceerd in: (2021)

Substandard and Falsified Medicines in Myanmar
door: Mirai Sakuda, et al.
Gepubliceerd in: (2020-03-01)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance
door: Cavany, S, et al.
Gepubliceerd in: (2023)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance
door: Sean Cavany, et al.
Gepubliceerd in: (2023-10-01)

How to achieve international action on falsified and substandard medicines.
door: Attaran, A, et al.
Gepubliceerd in: (2012)

The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists
door: Veronika J Wirtz, et al.
Gepubliceerd in: (2019-07-01)

Combatting substandard and falsified medicines: a view from Rwanda.
door: Agnes Binagwaho, et al.
Gepubliceerd in: (2013-01-01)

Substandard, falsified and unregistered medicines in Latin America, 2017-2018
door: Robin Rojas-Cortés
Gepubliceerd in: (2020-10-01)

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
door: Elizabeth Pisani, et al.
Gepubliceerd in: (2021-08-01)

Falsified and substandard medicines trafficking: A wakeup call for the African continent
door: Yusuf Hassan Wada, et al.
Gepubliceerd in: (2022-06-01)

Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications
door: Faris El-Dahiyat, et al.
Gepubliceerd in: (2021-10-01)

Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
door: Albert Petersen, et al.
Gepubliceerd in: (2017-01-01)

Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
door: Paul N Newton, et al.
Gepubliceerd in: (2022-08-01)

Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
door: Zabala, GA, et al.
Gepubliceerd in: (2022)

Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines
door: Tamara Akpobolokemi, et al.
Gepubliceerd in: (2022-01-01)

The economic impact of substandard and falsified antimalarial medications in Nigeria.
door: Sarah M Beargie, et al.
Gepubliceerd in: (2019-01-01)

The Future of Falsified and Substandard Medicine Detection: Digital Methods To Track and Authenticate Pharmaceutical Products
door: Naughton, B
Gepubliceerd in: (2018)

A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
door: Tabernero, P, et al.
Gepubliceerd in: (2022)

A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
door: Tabernero, P, et al.
Gepubliceerd in: (2019)

Technologies for detecting falsified and substandard drugs in low and middle-income countries.
door: Stephanie Kovacs, et al.
Gepubliceerd in: (2014-01-01)

Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab
door: Gesa Gnegel, et al.
Gepubliceerd in: (2022-07-01)

The concept of substandard (falsified and poor quality) industrial products and its types
door: K. A. Utarov, et al.
Gepubliceerd in: (2022-09-01)

The concept of substandard (falsified and poor quality) industrial products and its types
door: K. A. Utarov, et al.
Gepubliceerd in: (2022-09-01)

Substandard and falsified medical products: bibliometric analysis and mapping of scientific research
door: Waleed M. Sweileh
Gepubliceerd in: (2021-09-01)

Mobile apps for detecting falsified and substandard drugs: A systematic review.
door: Agustín Ciapponi, et al.
Gepubliceerd in: (2021-01-01)

Exploring pharmacists' perspectives about substandard and falsified medical products through interviews
door: A. Persson, et al.
Gepubliceerd in: (2024-03-01)

Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review
door: Biset Asrade Mekonnen, et al.
Gepubliceerd in: (2024-12-01)

Quantitative screening of the pharmaceutical ingredient for the rapid identification of substandard and falsified medicines using reflectance infrared spectroscopy.
door: Graham Lawson, et al.
Gepubliceerd in: (2018-01-01)

A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country
door: Daariimaa Khurelbat, et al.
Gepubliceerd in: (2020-05-01)

Substandard and falsified antimicrobials in selected east African countries: A systematic review.
door: Addisu Afrassa Tegegne, et al.
Gepubliceerd in: (2024-01-01)

Substandard and falsified antimicrobials in selected east African countries: A systematic review
door: Addisu Afrassa Tegegne, et al.
Gepubliceerd in: (2024-01-01)

Screening for substandard and falsified medicines in Nigeria using visual inspection and GPHF-Minilab analysis: lessons learnt for future training of health workers and pharmacy personnel
door: Micha Lächele, et al.
Gepubliceerd in: (2024-12-01)

A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality
door: McManus, D, et al.
Gepubliceerd in: (2020)

A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality
door: Dominic McManus, et al.
Gepubliceerd in: (2020-08-01)

Unveiling the Peril of Substandard and Falsified Medicines to Public Health and Safety in Africa: Need for All-Out War to End the Menace
door: Nafiu Aminu, et al.
Gepubliceerd in: (2017-01-01)

Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
door: Colleen R Higgins, et al.
Gepubliceerd in: (2023-01-01)

Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study
door: Colleen R. Higgins, et al.
Gepubliceerd in: (2023-01-01)

Small-scale dissolution test screening tool to select potentially substandard and falsified (SF) medicines requiring full pharmacopoeial analysis
door: Mohammad Sofiqur Rahman, et al.
Gepubliceerd in: (2021-06-01)

Cost savings of paper analytical devices (PADs) to detect substandard and falsified antibiotics: Kenya case study
door: Hui-Han Chen, et al.
Gepubliceerd in: (2021-03-01)

Substandard, Spurious, Falsely-Labelled, Falsified and Counterfeit (SSFFC) Drugs: Time to Take a Bitter Pill
door: Geetha Mani, et al.
Gepubliceerd in: (2016-10-01)